One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
HPV vaccination in south Asia: new progress, old challenges
doi : 10.1016/S1470-2045(22)00567-8
Volume 23, Issue 10, October 2022, Page 1233
Treatment options for metastatic hormone-sensitive prostate cancer
LouiseKostosaDeclan GMurphybc
Tissue-agnostic RET inhibition: can you trust your target?
Angelica D’Aiello, *Balazs Halmos
New combination therapy for thymic epithelial tumours
*Yasushi Shintani, Soichiro Funaki
War in Ukraine creates challenges for the cancer care system in Poland
Joanna A Didkowska, Klaudia Barańska,Urszula Wojciechowska, *Jerzy E Tyczyński
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA
*Changchuan Jiang, K Robin Yabroff, Micah Joseph Hill,Xuesong Han
HPV mRNA testing in cervical cancer screening
Paolo Giorgi Rossi, *Matejka Rebolj
HPV mRNA testing in cervical cancer screening – Authors' reply
*Marc Arbyn, Karen Canfell,Mario Poljak, Johannes Berkhof,Silvia de Sanjosé, Nicolas Wentzensen
Tempering optimism for MRI-guided focused ultrasound therapy
Philip Sutera, Michael Goldstein,Curtiland Deville Jr, *Aditya Halthore
Tempering optimism for MRI-guided focused ultrasound therapy – Authors' reply
*Behfar Ehdaie, Geoffrey A Sonn,Pejman Ghanouni
Ukraine's neighbouring countries accept the burden of cancer care for refugees
*Christiane Thallinger,Christoph C Zielinski
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma
Giuseppe Cabibbo†, Ciro Celsa†,Antonio D’Alessio†,Claudia A M Fulgenzi†,*David J Pinatoâ€
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma
Archana Sasi, Deepam Pushpam,*Sameer Bakhshi
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma
Sushant Chib, *Ajay Gogia
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma
*Osman Sütcüoğlu, AhmetÖzetOzan Yazıcı, NuriyeÖzdemir
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma – Authors' reply
*Patricia Pautier, Marie-Laure Tanguy,Baptiste Archambaud
ASTRO calls for a new value-based reimbursement structure for radiotherapy
Manjulika Das
New evidence that air pollution contributes substantially to lung cancer
Elizabeth Gourd
US FDA issues cancer warning linked to breast implants
Talha Khan Burki
The silent malignant mesothelioma epidemic: a call to action
1248*Nico van Zandwijk, John E J Rasko, Anthony M George,Arthur L Frank, Glen Reid
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
Weijie Gu, Weiqing Han, Hong Luo, Fangjian Zhou, Dalin He, Lulin Ma, Hongqian Guo, Chaozhao Liang, Tie Chong, Jun Jiang, Zhiwen Chen,Yong Wang, Qing Zou, Ye Tian, Jun Xiao, Jian Huang, Shaoxing Zhu, Qiang Dong, Xiaoping Zhang, Hanzhong Li, Xinfeng Yang, Chunxia Chen,Junliang Li, Chunlei Jin, Xiaojing Zhang, Dingwei Ye, on behalf of the CHART Investigators*
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Vivek Subbiah, Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander Spira, Jared Weiss, Masayuki Takeda, Yuichiro Ohe, Saad Khan,Kadoaki Ohashi, Victoria Soldatenkova, Sylwia Szymczak, Loretta Sullivan, Jennifer Wright, Alexander Drilon
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O’Brien*, Luis Paz-Ares*, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martinez-Marti,Martin Faehling, Masahiro Tsuboi, Jong-Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M Keller, Murielle Mauer, Nitish Jha,Rolf Stahel, Benjamin Besse†, Solange Peters†, on behalf of the EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 Investigators‡
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
Fabio Conforti, Paolo Andrea Zucali, Laura Pala, Chiara Catania, Vincenzo Bagnardi, Isabella Sala, Paolo Della Vigna, Matteo Perrino, Paola Zagami,Chiara Corti, Sara Stucchi, Massimo Barberis, Elena Guerini-Rocco, Benedetta Di Venosa, Fabio De Vincenzo, Nadia Cordua, Armando Santoro,Giuseppe Giaccone, Tommaso Martino De Pas
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial
Fred Saad, Antoine Thiery-Vuillemin, Pawel Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Ivo Kocak, Vincenzo Emanuele Chiuri, Jacek Jassem,Aude Fléchon, Charles Redfern, Jinyu Kang, Joseph Burgents, Christopher Gresty, Arnold Degboe, Noel WClarke
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
Alison C Tree, Peter Ostler, Hans van der Voet, William Chu, Andrew Loblaw, Daniel Ford, Shaun Tolan, Suneil Jain, Alexander Martin,John Staffurth, John Armstrong, Philip Camilleri, Kiran Kancherla, John Frew, Andrew Chan, Ian S Dayes, Aileen Duffton, Douglas H Brand,Daniel Henderson, Kirsty Morrison, Stephanie Brown, Julia Pugh, Stephanie Burnett, Muneeb Mahmud, Victoria Hinder, Olivia Naismith,Emma Hall*, Nicholas van As*, on behalf of the PACE Trial Investigators
Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial
David Hui, Veronica Puac, Zeena Shelal, Rony Dev, Sandra K Hanneman, Kristofer Jennings, Hilary Ma, Diana L Urbauer, Sanjay Shete, Frank Fossella,Zhongxing Liao, George Blumenschein Jr, Joe Y Chang, Michael O’Reilly, Saumil J Gandhi, Anne Tsao, Donald A Mahler, Eduardo Bruera
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis
Brett L Ecker*, Jasme Lee*, Lily V Saadat, Thomas Aparicio, Florian E Buisman, Vinod P Balachandran, Jeffrey A Drebin, Kiyoshi Hasegawa,William R Jarnagin, Nancy E Kemeny, T Peter Kingham, Bas Groot Koerkamp, Norihiro Kokudo, Yutaka Matsuyama, Guillaume Portier,Leonard B Saltz, Kevin C Soares, Alice C Wei, Mithat Gonen†, Michael I D’Angelicaâ€
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
Cathrine Lund Lorentzen, John B Haanen,ÖzcanMet, Inge Marie Svane
Evolution of the joint International Atomic Energy Agency (IAEA), International Agency for Research on Cancer (IARC), and WHO cancer control assessments (imPACT Reviews)
Igor Veljkovikj, André M Ilbawi, Felipe Roitberg, Silvana Luciani, Prebo Barango, Marilys Corbex, Gampo Dorji, Nalika Gunawardena, Sonali Johnson,Arsen Juric, Kendall Siewert, Giovanni Saporiti, Marianna Nobile, Catherine Sauvaget, Janaki Vidanapathirana, Beverley Wright, Kennedy Lishimpi,Dilyara Kaidarova, Alicia Pomata, Anne Malick, Jean Marie Dangou, May Abdel-Wahab, Elisabete Weiderpass, Bente Mikkelsen, Lisa M Stevens
European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making
Nicolaus Andratschke*, Jonas Willmann*, Ane L Appelt, Najlaa Alyamani, Panagiotis Balermpas, Brigitta G Baumert, Coen Hurkmans,Morten Høyer, Johannes A Langendijk, Orit Kaidar-Person, Yvette van der Linden, Icro Meattini, Maximilian Niyazi, Nick Reynaert,Dirk De Ruysscher, Stephanie Tanadini-Lang, Peter Hoskin, Philip Poortmans, Carsten Nieder
Unusual purpura as a first sign of amyloid light chain amyloidosis
Yufen Li, Yiqun Jiang
